An ensemble of structures of Burkholderia pseudomallei 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase by Davies, Douglas R. et al.
structural communications
1044 doi:10.1107/S1744309111030405 Acta Cryst. (2011). F67, 1044–1050
Acta Crystallographica Section F
Structural Biology
and Crystallization
Communications
ISSN 1744-3091
An ensemble of structures of Burkholderia
pseudomallei 2,3-bisphosphoglycerate-dependent
phosphoglycerate mutase
Douglas R. Davies,
a,b* Bart L.
Staker,
a,b Jan A. Abendroth,
a,b
Thomas E. Edwards,
a,b Robert
Hartley,
a,b Jess Leonard,
a,b
Hidong Kim,
a,b Amanda L.
Rychel,
c Stephen N. Hewitt,
c
Peter J. Myler
a,d,e and Lance J.
Stewart
a,b
aSeattle Structural Genomics Center for
Infectious Disease (http://www.ssgcid.org),
USA,
bEmerald BioStructures Inc., 7869 NE Day
Road West, Bainbridge Island, WA 98110, USA,
cDepartment of Biology, University of
Washington, Seattle, WA 98195-1800, USA,
dSeattle Biomedical Research Institute,
307 Westlake Avenue North, Suite 500, Seattle,
WA 98109, USA, and
eDepartments of Global
Health, Medical Education and Biomedical
Informatics, School of Medicine, University of
Washington, Box 357230, Seattle, WA 98195,
USA
Correspondence e-mail: ddavies@embios.com
Received 12 February 2011
Accepted 28 July 2011
PDB References: 2,3-bisphosphoglycerate-
dependent phosphoglycerate mutase, 3ezn;
3fdz; 3gp3; 3gp5; 3gw8; 3lnt.
Burkholderia pseudomallei is a soil-dwelling bacterium endemic to Southeast
Asia and Northern Australia. Burkholderia is responsible for melioidosis, a
serious infection of the skin. The enzyme 2,3-bisphosphoglycerate-dependent
phosphoglycerate mutase (PGAM) catalyzes the interconversion of 3-phos-
phoglycerate and 2-phosphoglycerate, a key step in the glycolytic pathway. As
such it is an extensively studied enzyme and X-ray crystal structures of PGAM
enzymes from multiple species have been elucidated. Vanadate is a phosphate
mimic that is a powerful tool for studying enzymatic mechanisms in phosphoryl-
transfer enzymes such as phosphoglycerate mutase. However, to date no X-ray
crystal structures of phosphoglycerate mutase have been solved with vanadate
acting as a substrate mimic. Here, two vanadate complexes together with an
ensemble of substrate and fragment-bound structures that provide a com-
prehensive picture of the function of the Burkholderia enzyme are reported.
1. Introduction
The phosphoglycerate mutase family encompasses enzymes that
catalyse the interconversion of 3-phosphoglycerate and 2-phospho-
glycerate. Most organisms utilize 2,3-bisphosphoglycerate-dependent
phosphoglycerate mutase (PGAM; EC 5.4.2.1) to accomplish this
reaction in glycolysis. In mammalian erythrocytes bisphospho-
glycerate mutase (BPGM; EC 5.4.2.4) is the predominant form.
PGAM converts 3-phosphoglycerate to 2-phosphoglycerate through
a ping-pong mechanism in which a phosphoenzyme transfers a
phosphate group from an active-site histidine to 3-phosphoglycerate
to form a 2,3-bisphosphoglycerate intermediate that subsequently
transfers the phosphate from the 3-position to yield the 2-phospho-
glycerate product and a reconstituted phosphoenzyme. The primary
reaction catalysed by BPGM is the conversion of 1,3-bisphospho-
glycerate to 2,3-bisphosphoglycerate. The mechanism of BPGM
begins with an unphosphorylated enzyme, the active-site histidine of
which performs a nucleophilic SN2 attack on the 1,3-bisphospho-
glycerate substrate to produce phosphohistidine and 3-phospho-
glycerate. The 20-hydroxyl group then performs a second nucleophilic
attack that transfers the phosphate from the active-site histidine to
the substrate, forming 2,3-bisphosphoglycerate. PGAM and BPGM
enzymes typically share  50% sequence identity and highly con-
served protein folds and readily catalyse each other’s primary reac-
tions, albeit with decreased efﬁciency.
Commensurate with its importance as a key enzyme in a primary
metabolic pathway, PGAM has been the subject of extensive inves-
tigation by X-ray crystallography. Three-dimensional crystal struc-
tures of PGAM have been solved from Gram-negative bacteria such
as Escherichia coli (Bond et al., 2002) and Thermus thermophilus
(PDB entry 1v37; M. Sugahara, S. Yokoyama, S. Kuramitsu, M.
Miyano, T. Iizuka & T. Kunishima, unpublished work), from the
Gram-positive pathogen Mycobacterium tuberculosis (Mu ¨ller et al.,
2005) and from Saccharomyces cerevisiae (Crowhurst et al., 1999), to
name a few. Here, we present six X-ray crystal structures of an
additional Gram-negative bacterial PGAM from Burkholderia
pseudomallei bound to various ligands.B. pseudomallei is a soil-dwelling bacterium endemic to Southeast
Asia and Northern Australia. Burkholderia is responsible for
melioidosis, a serious infection of the skin. As a key enzyme in
glycolysis and energy metabolism, PGAM is a potential target for
novel antibiotics. To this end, several X-ray crystal structures with
various ligands were solved for Burkholderia PGAM. While single-
crystal structures of important enzymes are informative, the most
valuable structural insights can be gleaned from ensembles of struc-
tures, which allow researchers to infer reaction mechanisms and may
even provide a basis for the rational design of small-molecule inhi-
bitors.
An important set of tools in the structural biologist’s repertoire are
the transition-state analogs. These are small molecules whose unique
chemistries allow the crystallographer to capture and visualize
structures that approximate the transient molecular species that
exist during chemical reactions. Perhaps the most widely studied
transition-state mimics are those for phosphoryl-transfer reactions,
particularly intermediates in SN2-type nucleophilic attack on phos-
phates that leads to new nucleophile–phosphorus bonds with the
breakage of phosphorus–oxygen bonds. The transition state for SN2
attack on phosphate is a trigonal bipyramidal arrangement of atoms
around the central phosphate, where the attacking nucleophile and
the leaving-group atom occupy the apical positions and the
nonbridging O atoms of the phosphate occupy the equatorial posi-
tions. Planar ions such as nitrate (NO3
 ) and tetraﬂuoroaluminate
(AlF4
 ) can provide informative transition-state mimics because they
are effective steric and electronic mimics of the planar PO3 moiety of
the transferred phosphate in the reaction. However, the most often
utilized and perhaps the best transition-state mimic is vanadate, a
reactive phosphate mimic which, in addition to adopting a trigonal
bipyramidal geometry in many phosphoryl-transfer enzyme active
sites, readily forms long ( 2A ˚ ) bonds along its apical positions. Here,
we also present two vanadate-bound structures of Burkholderia
PGAM that provide the most accurate transition-state analog struc-
tures for this class of enzymes to date.
Beyond the structures of substrates, products and transition-state
mimics, which can provide insight into reaction mechanisms,
fragment-bound structures of enzymes can provide additional
chemical starting points for small-molecule inhibitor design.
Fragment-based drug-discovery methods (reviewed in Rees et al.,
2004; Congreve et al., 2008) are focused on the discovery of small
molecules that bind to speciﬁc sites on macromolecular targets. An
ensemble of fragment-bound structures can be used to map binding
sites and assist in structure-based drug-design efforts. Here, we
present two examples of fragment-bound structures: one from a
metabolite-based fragment collection called Fragments of Life
(Davies et al., 2009) and one from an alternate crystal form grown in
malonate. Taken together, the ensemble of X-ray crystal structures of
B. pseudomallei PGAM presented here provides one of the most
complete pictures of a phosphoglycerate mutase-family enzyme and
its interactions with small molecules elucidated to date.
2. Methods
2.1. Protein expression and purification
Full-length 2,3-bisphosphoglycerate-dependent phosphoglycerate
mutase (accession ID YP_332076) was ampliﬁed from puriﬁed
B. pseudomallei strain 1710b genomic DNA (kindly provided by
Rajinder Kaul, University of Washington) using the following primer
sequences: FWD primer 50-CTCACCACCACCACCACCATATGT-
ACAAGCTCGTTCTCATCCG-30 and REV primer 50-ATCCTAT-
CTTACTCACTTATGCCGCGGACTTGCCCTGCT-30 (Invitrogen).
The PCR conditions were optimized for the high G+C content of
Burkholderia DNA. Each 50 ml reaction consisted of 27.1 mld H 2O,
10 ml Phusion GC Buffer (5 ) with 7.5 mM MgCl2 (NEB, catalog No.
F-519), 0.4 ml2 5 m M dNTPs (Qiagen, catalog No. 201912), 2 ml
DMSO, 0.5 ml (1 U) Phusion High-Fidelity DNA polymerase (NEB,
catalog No. F-530L), 4 ml FWD primer, 4 ml REV primer and 2 ml
(20 ng) B. pseudomallei 1710b genomic DNA; thermal cycling con-
ditions were 361 K for 30 s, followed by 30 cycles of 361 K (15 s),
338 K (15 s) and 345 K (30 s) and a ﬁnal extension of 345 K for 3 min
(Bio-Rad, MJ Research PTC-200 thermal cycler). PCR amplicons
were run on agarose gel to verify the expected size of the ampliﬁed
gene; the band was then excised from the gel and extracted from
the agarose using a QiaQuick kit (Qiagen, catalog No. 28181). The
puriﬁed PCR product was cloned into the expression vector BG1861,
which expresses the protein product fused to a minimal noncleavable
polyhistidine tag (MAHHHHHH) on the N-terminus, by ligation-
independent cloning (LIC; Aslanidis & de Jong, 1990). Brieﬂy, the
puriﬁed PCR product was treated with T4 DNA polymerase in the
presence of the single nucleotide dCTP, creating overhangs arising
from the 30-to-50 speciﬁc exonuclease activity, and then annealed with
compatible, linearized and T4-treated BG1861 vector (Mehlin et al.,
2006). Annealed vector and insert were transformed into NovaBlue
competent cells (Novagen, catalog No. 71011-4) and plated on LB
agar (BD Difco LB Agar, Miller; BD, catalog No. 244520) with
50 mgm l
 1 each of ampicillin (Anatrace, catalog No. A1000) and
carbenicillin (Duchefa Biochemie, catalog No. C0109.0025) to select
for cells carrying the expression plasmid. The presence of the insert
was veriﬁed by colony PCR (using the above conditions, but the
colony was resuspended in water and used as template instead of
puriﬁed DNA). Plasmid DNA was puriﬁed (QIAprep Turbo Mini-
prep kit; Qiagen, catalog No. 27191) from 1 ml overnight cultures
and then transformed into the expression host E. coli BL21(DE3)-
R3-pRARE2 cells (a gift from SGC Toronto, Toronto, Ontario) by
heat-shock methods.
Starter cultures of 3 ml LB medium with appropriate antibiotics
were grown for  18 h at 310 K. ZYP-5052 auto-induction media was
prepared fresh as per Studier’s protocols (Studier, 2005). Antibiotics
were added to 2 l bottles of sterile auto-induction medium. The
bottles were inoculated with all of the overnight culture and then
grown for 72 h at 293 K in a LEX bioreactor. After 72 h growth, the
cell paste was pelleted by centrifugation at 4000g for 20 min at 277 K
and the resulting cell pellet was frozen in liquid nitrogen and stored at
193 K.
To prepare the protein, the cell paste was solubilized in lysis buffer
(25 mM HEPES, 500 mM NaCl, 5% glycerol, 30 mM imidazole, 0.5%
CHAPS, 10 mM MgCl2,1m M TCEP, 250 ng ml
 1 AEBSF pH 7.0)
with 0.01 g lysozyme added and sonicated for 30 min. After sonica-
tion, samples were treated with Benzonase and then centrifuged for
1 h to clarify the cell debris. The protein was puriﬁed by immobilized
metal-ion afﬁnity chromatography on nickel Sepharose columns with
equilibration buffer (25 mM HEPES pH 7.0, 500 mM NaCl, 5%
glycerol, 30 mM imidazole, 1 mM TCEP and 0.025% azide) using an
A ¨TKAexplorer. After thorough washing, bound protein was eluted
off the nickel column by addition of elution buffer (25 mM HEPES
pH 7.0, 500 mM NaCl, 5% glycerol, 1 mM TCEP, 250 mM imidazole
and 0.025% azide). Fractions from the nickel column were analyzed
for protein content and pooled. Peak fractions of protein were further
puriﬁed using a HiLoad 26/60 Superdex size-exclusion chromato-
graphy (SEC) column on an A ¨TKAprime at 1 ml min
 1 with a
running buffer consisting of 25 mM HEPES pH 7.0, 500 mM NaCl,
5%(v/v) glycerol, 0.025%(w/v) sodium azide and 2 mM DTT. SEC
structural communications
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pooled and concentrated in the SEC buffer to a ﬁnal concentration of
26 mg ml
 1. Protein samples were aliquoted into 100 ml volumes,
ﬂash-cooled in liquid nitrogen and stored at 193 K.
2.2. Crystallization
Crystals were grown by sitting-drop vapour diffusion by mixing
0.4 ml reservoir solution with 0.4 ml protein solution over a reservoir
volume of 80 ml in a 96-well Compact Jr plate (Emerald BioSystems).
For PDB entries 3ezn, 3gp3, 3gp5, 3gw8 and 3fdz, crystals were
harvested from a single drop in the primary crystallization screen
set up at 289 K. The reservoir was condition B4 of the Cryo screen
(Emerald BioSystems) and consisted of 5% PEG 1000, 10% glycerol,
30% PEG 600 and 100 mM MES pH 7.5. The drop contained dozens
of plate-like crystals smaller than 50 mm in size. A single crystal was
harvested with a Litho Loop and ﬂash-cooled for data collection
by plunging the loop directly into liquid nitrogen. Following data
collection and solution of the unliganded structure, four additional
ligand-bound structures were obtained by soaking. The 2-phospho-
serine and 2,3-bisphosphoglycerate/3-phosphoglycerate structures
were obtained via overnight soaks in crystallization reservoir solution
supplemented with 20 mM 2-phosphoserine or 20 mM 3-phospho-
glycerate, respectively. The vanadate–glycerol structure was obtained
via a 2 h soak in crystallization reservoir solution supplemented with
2m M activated sodium orthovanadate. Activated vanadate was
prepared following the method of Gordon (1991). Brieﬂy, sodium
orthovanadate was dissolved in water, adjusted to pH > 10.0 with
concentrated sodium hydroxide and heated at 368 K for  5m i n .T h e
process of adding sodium hydroxide and heating was repeated until
the pH remained above 10 and the solution remained clear and
colorless upon cooling. The vanadate–3-phosphoglycerate structure
was obtained via a 3 h soak in crystallization reservoir solution
supplemented with 2 mM activated sodium orthovanadate and
20 mM 3-phosphoglycerate. Structure 3lnt was solved from a crystal
grown by sitting-drop vapour diffusion as described above but was
obtained from condition C3 of the Index HT screen (Hampton
Research), with a reservoir solution consisting of 2.4 M sodium
malonate pH 7.0. A single crystal was transferred to a cryoprotectant
consisting of 2.4 M sodium malonate pH 7.0 plus 25%(v/v) ethylene
glycol prior to ﬂash-cooling for data collection.
2.3. Data collection and structure determination
Data for structures 3ezn, 3gp5 and 3fdz were collected using a
Rigaku MicroMax-007 HFrotating-anode X-ray source with VariMax
Cu-HF optics and a Saturn 944 CCD detector. Data for structures
3gw8 and 3lnt were collected using a Rigaku SuperBright FR-E+
X-ray generator with Osmic VariMax HF optics and a Saturn 944+
CCD detector. Data for structure 3gp3 were collected on beamline
structural communications
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Table 1
Data-collection statistics.
Values in parentheses are for the highest of 20 resolution shells.
Ligand Apo 2-Phosphoserine
Vanadate +
3-phosphoglycerate Vanadate (+ glycerol)
2,3-Bisphosphoglycerate +
3-phosphoglycerate Malonate
Space group P1 P1 P1 P1 P1 P65
Unit-cell parameters
a (A ˚ ) 44.94 49.26 44.75 45.18 44.39 119.62
b (A ˚ ) 49.08 72.05 48.98 49.11 48.48 119.62
c (A ˚ ) 62.11 78.04 62.96 62.59 62.09 103.67
  ( ) 107.11 107.96 105.46 106.42 106.03 90.0
  ( ) 91.19 93.00 91.15 91.18 91.54 90.0
  ( ) 107.81 104.20 107.42 107.61 107.50 120.0
Wavelength (A ˚ ) 1.5418 0.97934 1.5418 1.5418 1.5418 1.5418
Resolution range (A ˚ ) 50.0–2.10 (2.15–2.10) 50.0–1.50 (1.54–1.50) 50.0–2.25 (2.33–2.25) 50.0–1.93 (1.98–1.93) 50.0–2.25 (2.31–2.25) 50.0–2.10 (2.15–2.10)
Unique reﬂections 26261 149575 21960 34058 20934 49080
Multiplicity 3.7 (3.6) 3.1 (2.1) 2.0 (1.9) 3.4 (2.20) 3.4 (3.0) 7.4 (7.0)
Completeness (%) 93.7 (83.2) 95.3 (84.9) 94.5 (82.1) 92.8 (80.4) 93.4 (90.5) 99.9 (99.9)
Rmerge† (%) 4.1 (13.7) 8.1 (59.8) 6.80 (24.5) 6.60 (30.1) 7.1 (34.5) 8.50 (72.1)
Mean I/ (I) 25.7 (9.9) 18.1 (1.4) 13.1 (3.45) 22.0 (2.89) 11.43 (2.60) 18.8 (2.30)
† Rmerge =
P
h
P
i jIiðhÞ h IðhÞij=
P
h
P
i IiðhÞ.
Table 2
Reﬁnement and model statistics.
Values in parentheses are for the highest of 20 resolution shells.
Ligand Apo 2-Phosphoserine
Vanadate +
3-phosphoglycerate Vanadate (+ glycerol)
2,3-Bisphosphoglycerate +
3-phosphoglycerate Malonate
Resolution range (A ˚ ) 50.0–2.10 (2.15–2.10) 50.0–1.50 (1.54–1.50) 50.0–2.25 (2.33–2.25) 50.0–1.93 (1.98–1.93) 50.0–2.25 (2.31–2.25) 50.0–2.10 (2.15–2.10)
Rcryst† 0.150 (0.147) 0.237 (0.429) 0.171 (0.215) 0.187 (0.260) 0.183 (0.252) 0.170 (0.222)
Rfree† 0.204 (0.227) 0.268 (0.425) 0.234 (0.316) 0.227 (0.308) 0.256 (0.331) 0.196 (0.251)
R.m.s.d. bonds (A ˚ ) 0.020 0.027 0.019 0. 009 0.013 0.015
R.m.s.d. angles ( ) 1.650 2.114 1.754 1. 200 1.526 1.385
Protein atoms 3726 7424 3771 3701 3668 3808
Nonprotein atoms 402 850 298 409 263 283
Mean B factor (A ˚ 2) 14.88 19.20 22.90 22.54 23.70 27.65
Ligand B factor‡ (A ˚ 2) N/A 23.32 19.66 31.04 30.00 33.57
Residues in favored region (%) 83.7 85.8 83.3 87.2 82.1 83.9
Residues in allowed region (%) 98.7 98.9 98.9 98.7 99.3 99.2
MolProbity score [percentile] 1.90 [86th] 1.69 [70th] 1.78 [95th] 1.31 [99th] 2.01 [87th] 1.18 [100th]
PDB code 3ezn 3gp3 3gp5 3gw8 3fdz 3lnt
† Rcryst =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj. The free R factor was calculated using 5% of the reﬂections omitted from the reﬁnement (Winn et al., 2011). ‡ Ligand B factors are for
ligands in the active sites of the protein monomers at 100% occupancy., Ligands from solvent (PEG, glycerol etc.) were not included in the calculation of these B factors.23-ID-D of the Advanced Photon Source in Argonne, Illinois, USA.
Surprisingly, this crystal was not isomorphous to the other four from
the same drop and its triclinic unit cell was almost twice the size of the
others. The data sets were reduced and scaled using the HKL-2000
structural communications
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Figure 1
Ensemble of B. pseudomallei PGAM structures. Protein models are displayed in green as ribbon structures, with key residues rendered as stick structures. Ligands are shown
in stick representation with C atoms colored yellow. Wire mesh represents the 3.0  level of the (Fo   Fc) OMIT map calculated for the ﬁnal structure with ligands removed.
Polar contacts are rendered as red dashed lines. All ligands were modelled at 100% occupancy, with the exception of the tetrahedral vanadate in 3gw8 (50%) and the two
alternate conformations of glycerol in 3gw8 (50% each). In all cases occupancies were held constant and not reﬁned. (a) PDB entry 3ezn, apo structure; (b) PDB entry 3fdz
subunit B, bound 3-phosphoglycerate with phosphohistidine; (c) PDB entry 3fdz subunit A, bound 2,3-bisphosphoglycerate; (d) PDB entry 3gw8, vanadate–glycerol
complex; (e) PDB entry 3gp5, vanadate–3-phosphoglycerate complex; (f) PDB entry 3gp3, bound 2-phosphoserine; (g) PDB entry 3lnt, malonate-bound structure.software suite (Otwinowski & Minor, 1997), except for structure 3lnt,
which was processed using XDS (Kabsch, 2010).
The unliganded structure of B. pseudomallei PGAM was solved by
molecular replacement using Phaser from the CCP4 software suite
(Winn et al., 2011) with the C-terminal domain (residues 129–336) of
the Chlorobium tepidum BchU protein (PDB entry 1x19; Wada et al.,
2006) as the search model, with non-identical side chains truncated
by the program CHAINSAW. Molecular replacement was successful,
despite the low sequence identity ( 19%) between the search model
and the target. The structure was initially rebuilt with ARP/wARP,
followed by numerous reiterative rounds of reﬁnement in REFMAC
and manual building using the Crystallographic Object-Oriented
Toolkit (Coot; Emsley & Cowtan, 2004). Subsequent structures were
solved by molecular replacement using the protein-only model of
3ezn as the search coordinates. Ligand-bound models were built by
alternating rounds of reﬁnement with REFMAC and manual building
and inspection in Coot. Data-collection and reﬁnement statistics are
given in Tables 1 and 2.
3. Results and discussion
3.1. Ensemble of B. pseudomallei structures
The ﬁrst of the B. pseudomallei PGAM structures to be solved was
3ezn, the ‘apo’ structure without ligands (the only nonprotein atoms
in the model other than solvent waters are part of polyethylene glycol
molecules on the surface of the proteins). The apo structure con-
tained a dimer in the asymmetric unit and the active site of each
protein monomer was unencumbered by crystal-packing interactions,
contained a few ordered solvent water molecules and showed no
evidence of phosphorylation of the active-site residue His9. Four of
the ﬁve ligand-bound structures that followed (PDB entries 3fdz,
3gp3, 3gp5 and 3gw8) were solved from soaked crystals harvested
from the exact same 0.8 ml sitting-drop vapor-diffusion well that
yielded the apo structure. Thus, the unliganded structure is an
excellent control which represents the initial state of the enzyme in
the crystal form prior to the addition of ligands.
Structure 3fdz was obtained via an overnight soak of a single
crystal in crystallization solution supplemented with 20 mM 3-phos-
phoglycerate. Unexpectedly, the resultant crystal structure exhibited
electron density consistent with the presence of 2,3-bisphospho-
glycerate in one of the monomers and 3-phosphoglycerate along with
phosphorylation at His9 in the other. These observations strongly
suggest that PGAM is active in the P1 crystal form and that the 2,3-
bisphosphoglycerate intermediate was generated by enzymatic con-
version of 3-phosphoglycerate. The presence of two distinct stages of
the PGAM catalytic cycle in the same crystal structure is a serendi-
pitous discovery, but difﬁcult to rationalize in light of the observed
structure. The two monomers in the asymmetric unit are related by
noncrystallographic symmetry and thus are not identical, providing
distinct chemical and structural environments for each active site.
However, least-squares superposition of the two monomers (as
implemented in Coot; Emsley & Cowtan, 2004) revealed an r.m.s.
deviation of 0.70 for the apo structure and of 0.63 for the 3-phos-
phoglycerate-soaked structure. Closer inspection shows that the
active-site regions are even more similar, with all ligand-contacting
amino-acid side chains except Arg115 adopting nearly identical
conformations (Fig. 1).
The ensemble of Burkholderia PGAM structures also includes two
fragment-bound models. The term ‘fragments’ is used in the context
of fragment-based drug discovery, where a fragment is any small
molecule of molecular weight approximately less than 300 Da.
Fragment-screening efforts can often lead to the identiﬁcation of
small molecules that bind to protein targets with relatively low afﬁ-
nity but with high speciﬁcity. The utility of fragments for structure-
based inhibitor design is that they allow researchers to probe protein
binding pockets for sites capable of binding different chemical
groups, which may subsequently be linked through chemical
elaboration to create larger high-afﬁnity inhibitors. The structures of
PGAM bound to 2-phosphoserine and malonate (PDB entries 3gp3
and 3lnt, respectively) are examples of nonsubstrate fragment mole-
cules that may inform inhibitor design.
The small molecule 2-l-phosphoserine was selected from the
Fragments of Life library (Emerald BioStructures) based on its
structural similarity to 3-d-phosphoglycerate. Both 2-phosphoserine
structural communications
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Figure 2
Comparison of vanadate- and AlF4
 -bound structures of phosphoglycerate mutase enzymes. Pairwise alignments were performed using the SSM superpose function from the
CCP4 program suite. (a) Superposition of the structures from PDB entries 3gw8 (vanadate–glycerol, pale green) and 3gp5 (vanadate–3-phosphoglycerate, bright green). (b)
Superposition of the structures from PDB entries 3gp5 (vanadate–3-phosphoglycerate, green) and 2f90 (human erythrocyte BPGM with bound tetraﬂuoroaluminate and
3-phosphoglycerate, orange). (c) Superposition of the structures from PDB entries 3gp5 (vanadate–3-phosphoglycerate, green) and 1e59 (E. coli PGAM with bound
tetravanadate, yellow).and 3-phosphoglycerate share a secondary carboxylate group and
a phosphate linkage. The key differences between the two small
molecules are that they have inverted chirality at the C2 atom and
serine has an amino group in place of a hydroxyl. PGAM tolerates
binding of this nonsubstrate molecule, probably owing to the nearly
unchanged relative positions of the phosphate and carboxylate
moieties, which are highly coordinated by the active-site residues
Thr21, Gly22, Tyr90, Lys98, Arg114 and Arg115. The replacement of
the secondary hydroxyl by a secondary amine is expected to make
2-phosphoserine unreactive with PGAM and the fragment is
expected to be an inhibitor. Also of note in the 2-phosphoserine
structure is the unusual structure of the phosphorylated histidine
residue His9. The bond angles between the phosphate O atoms, the
central P atom and His9 N
"2 are close to 90  and the P—N
"2 distance
is long for a nitrogen–phosphorus bond at  2A ˚ . This geometry is
reminiscent of the planar arrangement around phosphate observed
in glucose 1-phosphate-bound  -phosphoglucomutase (Lahiri et al.,
2003; PDB entry 1o08). The  -phosphoglucomutase structure was
interpreted as a true transition state for phosphate transfer captured
in a crystal structure. Unlike the  -phosphoglucomutase structure,
where there is an  2A ˚ distance between the P atom and both the
enzyme nucleophile and the substrate leaving group, there is a very
long (>3.8 A ˚ ) distance between the P atom and the nearest atom of
the 2-phosphoserine.
The second fragment-bound structure (PDB entry 3lnt) contains
malonic acid bound in the active site. The dicarboxylic acid adopts
a bound conformation that places one carboxylate group in the
carboxylate-binding pocket formed by Thr21 and Gly22, while the
other carboxylate group is oriented towards His9 near the positively
charged region responsible for binding the transferred phosphate.
This structure was obtained from a different crystal form that was
grown from 2.4 M sodium malonate. The alternate crystal packing in
the malonate-grown crystals coincided with a signiﬁcant shift of the
 -helix containing residues Arg114 and Arg115 relative to its position
in the P1 crystal form. Arg114 and Arg115 are largely responsible for
binding the 3-phosphate of the substrate molecule and it is unknown
whether the malonate-grown crystal form could accommodate
3-phosphoglycerate binding. While useful for elucidating the binding
mode of a dicarboxylic acid fragment, this crystal form is completely
unsuitable for soaking of additional ligands since the crystallant itself
is also the ligand.
3.2. Vanadate structures
Vanadate is a reactive metal oxoanion that is capable of adopting
structures that mimic the transition state of phosphoryl-transfer
reactions (Lindquist et al., 1973; VanEtten et al., 1974). Vanadate has
been successfully used to capture transition-state mimics in X-ray
crystal structures of a variety of enzymes that perform chemistry on a
phosphate group. A survey of the crystallographic literature in 2004
(Davies & Hol, 2004) revealed vanadate to be a versatile molecular
tool that had elucidated transition-state structures for enzymes in
four of the six EC categories of enzymes from crystals grown at
pH 5.0–7.8. Based on this history, we reasoned that our crystals
of Burkholderia PGAM (at pH 7.5) were excellent candidates for
soaking with vanadate compounds.
E. coli PGAM has previously been subjected to crystallographic
investigation with vanadate (Bond et al., 2002; PDB entry 1e59).
However, rather than binding in a trigonal bipyramidal conﬁguration
at the nucleophilic histidine, a polymer of four tetrahedral vanadate
moieties was visualized in the substrate-binding site. The binding of
tetravanadate rather than a monomeric transition-state mimic vana-
date species in the E. coli PGAM structure was likely to be a result
of the methods employed for crystal growth. The published crystal-
lization conditions listed the use of 100 mM NaVO3 rather than
‘activated’ Na3VO4 and described the slow development of a yellow
color consistent with vanadate polymerization during the period of
crystal growth. Bond and coworkers hypothesized that the tetra-
vanadate species visualized in their structure represented not a
transition-state mimic but rather provided the locations of preferred
binding sites for carboxylate and phosphate anions. This hypothesis
is strengthened by comparison of the tetravanadate structure with the
Burkholderia vanadate-bound structures, which are proper transi-
tion-state mimics (Fig. 2c).
Two vanadate structures with Burkholderia PGAM were obtained,
each with additional molecular entities covalently bound to the
vanadate. One of the properties that makes vanadate such a powerful
transition-state mimic is its ability to exchange its O atoms and
derivatize with a variety of ligands. Low-order covalent bonds can be
formed between the V atom and the apical ligands of the trigonal
bipyramidal conﬁguration representing the attacking nucleophile and
leaving group. Derivitization of vanadate by glycerol is not without
precedent; in a crystal structure of human tyrosyl DNA phospho-
diesterase, glycerol from the cryoprotectant became covalently
bound to vanadate at the active site at one apical and one equatorial
position (Davies et al., 2002). Glycerol was present in the crystal-
lization and soaking solutions of PGAM at 10%(v/v) concentration
and its visualization in the crystal structure (PDB entry 3gw8) was not
unexpected. The crystal structure revealed that the glycerol O2 atom
had become the apical ligand of vanadate opposite the N
"2 atom of
His9. In this arrangement, glycerol adopts a conformation and posi-
tion similar to the glycerate moiety of the natural PGAM substrate.
Interestingly, electron density consistent with a tetrahedral oxoanion,
presumed to be VO4, was observed adjacent to the bound glycerol,
occupying the position of the binding site for the 3-phosphate of the
substrate. Difference electron density was weaker for the tetrahedral
vanadate, but the presence of vanadium was conﬁrmed by calculation
of an anomalous difference map (data not shown). The tetrahedral
vanadate oxoanions were modelled at 50% occupancy.
An even more accurate transition-state mimic was achieved in
structure 3gp5. In this structure, 20 mM 3-phosphoglycerate was
present in the soaking solution in addition to vanadate. The resultant
structure was comprised of vanadate in a trigonal bipyramidal con-
ﬁguration, with the N
"2 atom of His9 and the O2 atom of 3-phos-
phoglycerate contributing apical ligands. The three equatorial atoms
of vanadate were approximately coplanar and formed polar contacts
with theside chains of Arg8, Asn15, Arg60, Glu87 and His182 andthe
backbone N atom of Gly183. This arrangement of the equatorial O
atoms is nearly identical in the glycerol-bound structure, indicating
that the vanadate is providing an accurate structure of the transition-
state structure of phosphate despite the presence of a nonsubstrate
ligand such as glycerol. The only similar example of a transition-state
mimic for a phosphoglycerate mutase-family enzyme in the PDB is
a structure of human erythrocyte bisphosphoglycerate mutase with
tetraﬂuoroaluminate and 3-phosphoglycerate (Wang et al., 2006; PDB
entry 2f90). In this structure, the square planar AlF4
  ion occupies
nearly the same relative position as vanadate. When compared with
the vanadate structures, the interatomic distances from the central
Al atom are similar to the interatomic distances around vanadium.
However, tetraﬂuoroaluminate is a less accurate transition-state
mimic because it has four equatorial F atoms instead of three equa-
torial O atoms as found in vanadate.
Together with the 3-phosphoglycerate-bound and 2,3-bisphospho-
glycerate-bound structures, the vanadate–3-phosphoglycerate struc-
structural communications
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reaction proceeding from phosphoenzyme plus substrate to transition
state to enzyme plus intermediate product.
4. Conclusions
The ensemble of six X-ray crystal structures of B. pseudomallei
PGAM presented here provides for the ﬁrst time a comprehensive
view of a phosphoglycerate mutase enzyme complete with bound
ligands encompassing substrate, intermediate, transition-state mimic
and fragment-bound structures. Taken together, these crystal struc-
tures allow the deﬁnitive identiﬁcation of key amino-acid residues
involved in substrate binding and catalysis. The inclusion of two
metabolite-like fragment structures in the ensemble (2-phospho-
serine and malonate) provides starting points for elucidating ligand-
binding ﬂexibility and potential for small-molecule inhibitor design.
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